Every Peptide Joe Rogan Has Discussed on JRE

The Joe Rogan Experience reaches tens of millions of listeners per episode, and Rogan’s peptide advocacy has arguably done more to bring these compounds into mainstream awareness than any other single media source. Unlike Huberman Lab, which treats peptides as a structured educational topic, Rogan discusses peptides organically across many episodes – during conversations about training injuries, ageing, performance, and political regulation.

The table below indexes the most significant JRE episodes where peptides were a substantive topic of discussion.

Episode	Guest	Date	Peptides / Topics Covered
#1683	Andrew Huberman	Jul 2021	BPC-157 for elbow tendinitis; Rogan’s first major on-air peptide endorsement
#1873	Brigham Buhler	Sep 2022	Peptide therapy overview; Ways2Well; compounding pharmacies
#2079	Brigham Buhler	Dec 2023	FDA peptide restrictions; compounding pharmacy regulation; BPC-157 access
#2195	Andrew Huberman	Aug 2024	Peptide science, mechanisms, BPC-157 and TB-500 as repair signals
#2376	Brigham Buhler	Sep 2025	GLP-1 compounding vs branded; FDA regulation; peptide industry politics; BPC-157
#2461	RFK Jr.	Feb 27, 2026	14-of-19 peptide reclassification announcement; Category 2 reversal

Rogan has also mentioned peptides in passing during many other episodes and external appearances, including a widely shared June 2022 conversation on the Flagrant podcast with Andrew Schulz, where he described BPC-157 as “Wolverine shit” and credited it with resolving chronic elbow tendinitis from weightlifting and martial arts within two weeks.

The bottom line: Rogan’s peptide discussions span at least six major episodes from 2021 to 2026, evolving from personal injury recovery stories into substantive conversations about FDA regulation and political advocacy.

BPC-157 is Rogan’s most frequently discussed peptide by a wide margin. He has mentioned it dozens of times across episodes, and his personal narrative is what initially drove mainstream interest. Rogan has described using BPC-157 to treat elbow tendinitis caused by weightlifting and jiu-jitsu training, reporting that the pain resolved within approximately two weeks of beginning injections. He has also referenced a professional football player who reportedly recovered from a hamstring injury in two weeks using a BPC-157 and TB-500 combination. These are anecdotal accounts shared on a podcast, not clinical case reports.

TB-500 features in Rogan’s discussions primarily as the second half of the “Wolverine stack” – the BPC-157 and TB-500 combination that Rogan popularised. He frames it as a systemic repair complement to BPC-157’s more localised effects.

Rogan has also publicly discussed using ipamorelin (often in combination with CJC-1295) for growth hormone optimisation, and thymosin alpha-1 for immune support. These are referenced less frequently than BPC-157 but have been confirmed as part of his regimen in multiple episodes.

JRE Episode #2461 (February 27, 2026) was not just another peptide discussion – it was a regulatory event broadcast to one of the world’s largest audiences. HHS Secretary Robert F. Kennedy Jr. announced during the episode that approximately 14 of the 19 peptides on the FDA’s Category 2 restricted list would be moved back to Category 1 status, restoring the legal pathway for licensed compounding pharmacies to prepare them under physician prescription.

Kennedy described himself as a “big fan” of peptides and stated that he had used them personally. He argued that the Biden administration’s 2023 Category 2 designations had overstepped and driven patients toward an unregulated grey market. The FDA’s subsequent formal actions have confirmed the direction Kennedy indicated: on April 15, 2026, the FDA removed 12 peptides from Category 2, referring them to the PCAC for review. For a full timeline of these regulatory changes, see the RFK Peptide Reclassification Tracker.

The bottom line: Episode #2461 was the first time a sitting US Cabinet Secretary announced a pharmaceutical regulatory direction on an entertainment podcast, and it immediately triggered widespread confusion about whether peptides were “legal again” before any formal rule had changed.

Brigham Buhler (Episodes #1873, #2079, #2376)

Buhler, founder of Ways2Well (a functional and regenerative care clinic) and a former Eli Lilly pharmaceutical representative, has appeared on Rogan three times and has been the show’s primary peptide-focused guest. His September 2025 appearance (#2376, approximately 3 hours 21 minutes) was the most extensive peptide discussion in JRE history. Buhler argued that pharmaceutical companies were lobbying the FDA to restrict compounding pharmacies from producing cost-effective peptide alternatives, particularly around GLP-1 agonists like semaglutide. He positioned compounded peptides as producing superior fat loss outcomes with less muscle wasting than branded GLP-1 drugs when properly dosed.

His December 2023 episode (#2079) addressed the immediate aftermath of the FDA’s Category 2 restrictions and their impact on clinical peptide practices.

Andrew Huberman (Episodes #1683, #2195)

Huberman has appeared on JRE multiple times, with peptides featuring in at least two episodes. Episode #1683 (July 2021) is where Rogan first shared his personal BPC-157 tendinitis recovery story, with Huberman providing scientific context around angiogenesis and fibroblast migration. Episode #2195 (August 2024) revisited peptide science in the context of the evolving regulatory landscape. For the full index of what Huberman has covered on his own show, see the companion article: Peptides Huberman Has Discussed.

Across all episodes, Rogan and his guests have named the following peptides and related compounds in substantive discussion (excluding passing mentions of insulin and oxytocin as illustrative examples of what peptides are):

Compound	Context on JRE	Rogan Personal Use	PeptideGuider Guide
BPC-157	Injury healing, tendon repair, gut health	Yes – confirmed	BPC-157 Guide
TB-500	Systemic recovery, Wolverine stack	Yes – confirmed	TB-500 Guide
CJC-1295 + Ipamorelin	GH optimisation, ageing, recovery	Yes – confirmed	CJC-1295 / Ipamorelin Guides
Thymosin Alpha-1	Immune modulation, post-illness recovery	Yes – confirmed	TA-1 Guide
Semaglutide	Weight loss, compounding vs branded debate	Not confirmed	Semaglutide Guide
Sermorelin	GH secretagogue discussions	Not confirmed	Sermorelin Guide
Tesamorelin	GH secretagogue discussions	Not confirmed	Tesamorelin Guide

The scale of Rogan’s reach has had measurable effects on peptide demand. His BPC-157 endorsement is widely credited with driving the compound from niche bodybuilding forums into mainstream health awareness. Google Trends data shows consistent search interest spikes for “BPC-157” following JRE episodes where Rogan discusses it. The term “Wolverine stack” – which Rogan either coined or popularised – now generates steady search volume and has become a standard product offering among grey market peptide vendors.

The February 2026 RFK episode amplified this effect dramatically. Within hours of the broadcast, social media posts began circulating that “14 peptides are coming off the FDA’s Category 2 list” and that compounding restrictions were about to disappear. Multiple law firms published analyses within days clarifying that no formal FDA action had occurred. At least one firm, Frier Levitt, noted that Kennedy’s remarks reflected “political commentary on a podcast, not regulatory action.” The confusion between Kennedy’s statement of intent and actual FDA rulemaking persisted for weeks afterward.

As LegitScript’s data shows, online advertising of unauthorised peptide formulations grew nearly eightfold (678%) from 2022 to 2024 (LegitScript, December 2025). While this growth reflects multiple factors, Rogan’s consistent advocacy has been a significant demand-side driver.

The bottom line: Rogan’s podcast has functioned as the single most powerful demand driver for peptides in the English-speaking world, and his RFK episode blurred the line between media commentary and regulatory action in ways that took weeks to untangle.

Rogan consistently tells listeners to work with a physician. He has mentioned compounding pharmacy sourcing as distinct from grey market products. He has been transparent about the fact that his experience is personal and anecdotal, not clinical. And his willingness to platform guests with different perspectives – from physician advocates like Buhler to neuroscientists like Huberman to regulatory figures like Kennedy – gives listeners more angles than most single-source peptide content provides.

However, several gaps are worth noting. Rogan rarely discusses the quality of the evidence behind the peptides he endorses. The BPC-157 evidence base has a serious concentration problem: a STAT News investigation in February 2026 found that 35 of 36 studies came from a single laboratory group in Zagreb, and no completed randomised controlled trial in humans has been published. Rogan does not typically distinguish between animal and human evidence, between case reports and clinical trials, or between FDA-approved compounds and those with no regulatory pathway. His discussions also tend to understate the contamination risks of grey market products, despite the fact that no grey market peptide vial has been manufactured under pharmaceutical-grade conditions.

The regulatory landscape for the peptides Rogan endorses has changed substantially since his earliest discussions. BPC-157 was removed from the Category 2 list on April 15, 2026, and is now scheduled for PCAC review on July 23, 2026, for ulcerative colitis indication. TB-500 is in the same July 23 review batch. CJC-1295 and ipamorelin were previously cleared and remain available through compounding. Thymosin alpha-1 was voted against by the PCAC in December 2024 and is outside the current reclassification wave. For the full regulatory picture, see the Category 1 vs Category 2 explainer.

In the UK, peptides like BPC-157 and TB-500 are not scheduled as controlled substances but cannot be legally supplied for human use without authorisation. In Australia, BPC-157 has been Schedule 4 since June 2024 and TB-500 since 2016. For country-specific legality, see the US, UK, and Australian legality guides.